Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 93, Issue 12, Pages 1327-1339Publisher
SPRINGER
DOI: 10.1007/s00109-015-1313-z
Keywords
Adiponectin; Hepatic stellate cell; Inducible nitric oxide synthase; The AMP-activated protein kinase
Funding
- National Health and Medical Research Council of Australia [AP1004595, 1053206]
- Robert W. Storr Bequest
Ask authors/readers for more resources
Adiponectin protects against liver fibrosis, but the mechanisms have not been fully elucidated. Here, we showed that adiponectin upregulated inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) and protein expression in hepatic non-parenchymal cells, particularly in hepatic stellate cells (HSCs), and increased nitric oxide (NO2-/NO3-) concentration in HSC-conditioned medium. Adiponectin attenuated HSC proliferation and migration but promoted apoptosis in a NO-dependent manner. More advanced liver fibrosis with decreased iNOS/NO levels was observed in adiponectin knockout mice comparing to wide-type mice when administered with CCI4 while NO donor supplementation rescued the phenotype. Further experiments demonstrated that adiponectin-induced iNOS/NO system activation is mediated through adipoR2-AMPK-JNK/Erk1/2-NF-kappa B signaling. These data suggest that adiponectin inhibits HSC function, further limiting the development of liver fibrosis at least in part through adiponectin-induced NO release. Therefore, adiponectin-mediated NO signaling may be a novel target for the treatment of liver fibrosis. aEuro cent Adiponectin activates HSC iNOS/NO and SEC eNOS/NO systems. aEuro cent Adiponectin inhibits HSC proliferation and migration but promotes its apoptosis. aEuro cent Adiponectin inhibits CCL4-induced liver fibrosis by modulation of liver iNOS/NO. aEuro cent Adiponectin stimulates HSC iNOS/NO via adipoR2-AMPK-JNK/ErK1/2-NF-kappa B pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available